GlycoMimetics Inc (GLYC)
0.3158
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 10:49
GlycoMimetics Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.01M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | 0.075M |
| March 31, 2022 | |
| December 31, 2021 | 0.0176M |
| September 30, 2021 | 0.0866M |
| June 30, 2021 | 0.0001M |
| March 31, 2021 | 1.055M |
| December 31, 2020 | 0.1629M |
| September 30, 2020 | 1.00M |
| June 30, 2020 | |
| March 31, 2020 | 9.00M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 |
| Date | Value |
|---|---|
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | 0.0185M |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 0.0354M |
| September 30, 2015 | |
| June 30, 2015 | 20.04M |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 15.03M |
| March 31, 2014 | |
| December 31, 2013 | 0.0774M |
| September 30, 2013 | 0.0526M |
| June 30, 2013 | 0.0551M |
| March 31, 2013 | 3.808M |
| December 31, 2012 | 3.889M |
| September 30, 2012 | 3.827M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0001M
Minimum
Jun 2021
9.00M
Maximum
Mar 2020
1.268M
Average
0.0866M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| Arbutus Biopharma Corp | 1.339M |
| Revance Therapeutics Inc | 59.88M |
| FibroGen Inc | 46.33M |
| Cidara Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.824M |
| Total Expenses (Quarterly) | 5.721M |
| EPS Diluted (Quarterly) | -0.15 |
| Enterprise Value | 6.243M |
| Earnings Yield | -196.3% |
| Normalized Earnings Yield | -183.66 |